Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Liminatus Pharma ( (LIMN) ) has shared an update.
On February 6, 2026, Liminatus Pharma, Inc. entered a settlement and release agreement with Clear Street LLC, agreeing to issue 4,000,000 shares of its common stock in exchange for the surrender and cancellation of 805,377 outstanding warrants held by Clear Street. The share issuance was conducted without commissions and relied on an exemption from registration under the Securities Act.
As part of the settlement, both parties agreed to dismiss lawsuits pending in the U.S. District Courts for the Central District of California and the Southern District of New York, where a default judgment had been entered on September 11, 2025, against Liminatus for $7.5 million plus about $515,000 in interest. The agreement effectively resolves that judgment exposure and converts the company’s litigation liability into equity dilution, impacting existing shareholders but removing a significant legal and financial overhang.
More about Liminatus Pharma
Liminatus Pharma, Inc. operates in the pharmaceutical and biotechnology sector, focusing on the development and commercialization of drug products. The company issues common stock as part of its corporate financing activities and maintains relationships with institutional holders active in U.S. capital markets.
Average Trading Volume: 5,390,521
Technical Sentiment Signal: Sell
Current Market Cap: $49.8M
Find detailed analytics on LIMN stock on TipRanks’ Stock Analysis page.